Nuclear Medicine Scientist Joins MSU
Kurt R. Zinn, D.V.M., M.S., Ph.D., recently joined Michigan State University’s new Institute for Quantitative Health Science and Engineering and is the director of Nuclear Medicine. He is also a professor in the Department of Radiology and the Department of Biomedical Engineering. Recruited as part of MSU’s Global Impact Initiative, Zinn’s research focuses on the development of molecular imaging approaches for cancer diagnosis, treatment monitoring, and therapy. Zinn has contributed significantly to more than ten phase I clinical trials.
He earned his bachelor’s degree in chemistry, doctorate in veterinary medicine, a master of science degree in chemistry, and a doctoral degree in biochemistry at the University of Missouri-Columbia. As a scientist at the University of Missouri-Columbia Research Reactor, he developed methods for producing high specific activity radionuclides.
He then joined the University of Alabama at Birmingham radiology faculty in 1995. As professor of Radiology at the University of Alabama Birmingham, he also served as director of its Laboratory of Multimodality Imaging and the Preclinical Imaging Shared Facility. Zinn served as director of Radiology’s Division of Advanced Medical Imaging Research and was vice chair of Translational Research.
In 2015, he earned a Distinguished Investigator Award from the Academy of Radiology Research.
Oh P, Borgström P, Wikiewicz H, Li Y, Borgström BJ, Chrastina A, Iwata K, Zinn KR, Baldwin R, Testa JE, Schnitzer JE. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol 25 (3): 327-37, 2007. PMCID: PMC1979160
Zinn KR, Chaudhuri TR, Szafran AA, O’Quinn D, Weaver C, Dugger K, Lamar D, Kesterson RA, Wang X, Frank SJ. Noninvasive bioluminescence imaging in small animals. ILAR J 49 (1): 103-15, 2008. PMCID: PMC2614121
Szafran AA, Folks K, Warram J, Chanda D, Wang D, Zinn KR. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis. Cancer Biol Ther 8(12):1109-16, 2009. PMCID PMC4384463
Warram JM, Borovjagin AV, and Zinn KR. A genetic strategy for combined screening and localized imaging of breast cancer. Mol Imaging Biol 13(3): 452-61, 2011. PMCID PMC4359509
Warram JM, Sorace AG, Saini R, Borovjagin AV, Hoyt K, Zinn KR. Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles. Can Gene Ther 19(8):545-52, 2012. PMCID: PMC3417243
Richter JR, Mahoney M, Warram JM, Samuel S, Zinn KR. A Dual-Reporter, Diagnostic Vector for Detection and Localization of Prostate Cancer. Gene Ther 21(10):897-902, 2014. PMCID: PMC4350933
Zinn KR, Korb M, Samuel S, Warram JM, Dion D, Killingsworth C, Fan J, Schoeb T, Strong T, Rosenthal EL. IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus Macaques. Mol Imaging Biol 17(1):49-57, 2015. PMCID: PMC4318248
Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, Strong TV, Schmalbach C, Morlandt A, Agarwal G, Hartman YE, Carroll W, Richman JS, Clemons L, Nabell LM, Zinn KR. Safety and Tumor-specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clin Cancer Res 21(16): 3658-66, 2015.PMCID PMC4909371
Kasten BB, Azure MT, Schoeb TR, Fisher DR, Zinn KR. Imaging, biodistribution, and toxicology evaluation of 212Pb-TCMC-trastuzumab in nonhuman primates, Nuc Med Biol 43(7):391-396, 2016.
Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol 47:23-30, 2017. PMID: 28104527